West Pharmaceutical Services (NYSE:WST) Releases FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 8.850-9.050 for the period, compared to the consensus EPS estimate of 8.610. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion. West Pharmaceutical Services also updated its Q3 2026 guidance to 2.140-2.240 EPS.

West Pharmaceutical Services Trading Down 0.1%

Shares of WST opened at $358.87 on Thursday. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12-month low of $221.50 and a 12-month high of $367.66. The firm has a 50-day moving average price of $335.41 and a 200 day moving average price of $286.58. The firm has a market capitalization of $25.35 billion, a P/E ratio of 47.98, a P/E/G ratio of 2.91 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. West Pharmaceutical Services’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.45 earnings per share. Sell-side analysts forecast that West Pharmaceutical Services will post 8.6 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th will be issued a dividend of $0.22 per share. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.76%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on WST. Evercore reiterated an “outperform” rating and issued a $410.00 price objective on shares of West Pharmaceutical Services in a report on Monday, July 6th. Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Stephens reiterated an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective on the stock. Finally, KeyCorp upped their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Buy” and an average target price of $363.17.

Insider Activity

In other news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is currently owned by corporate insiders.

Institutional Trading of West Pharmaceutical Services

Hedge funds have recently modified their holdings of the stock. Empowered Funds LLC boosted its holdings in West Pharmaceutical Services by 16.1% in the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 224 shares during the period. Intech Investment Management LLC increased its holdings in West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after purchasing an additional 1,307 shares during the period. Acadian Asset Management LLC raised its position in West Pharmaceutical Services by 14.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock valued at $284,000 after purchasing an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after buying an additional 197 shares during the period. Finally, First Trust Advisors LP boosted its stake in shares of West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after buying an additional 29,067 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.